Kinases (Tyrosine Specific Protein)

Kinases (Tyrosine Specific Protein)

A small individual group of tyrosine kinase inhibitors is specifically targeting oncogenic fusion proteins. The expression of these proteins is caused by a reciprocal translocation between chromosomes, 9 and 22 in case of the BCR-ABL fusion protein. About 95% of the patients suffering from chronic myelogenous leukaemia show expression of this particular protein, yet it is also found in two other acute forms of leukaemia. Our product line includes both the very first drug registered on the market inhibiting this specific tyrosine kinase (Axon 1394: STI 571 or Imatinib (Novartis)), as well as well-known follow-up inhibitors, being more potent and/or more active against the emerging Gleevec/Glivec resistant BCR-ABL clones that originate from point mutations inside the kinase domain of the Bcr-Abl protein and disrupt the binding site of Imatinib on the tyrosine kinase (e.g. Axon 1392 and Axon 1396 (Dasatinib and Nilotinib resp.)

Read More
sort-descending
  • NVP-TAE684
    1416
    NVP-TAE684
    The price depends on the options chosen on the product page

    From $55.00

  • Crizotinib
    1660
    Crizotinib
    The price depends on the options chosen on the product page

    From $88.00

  • Alectinib
    1884
    Alectinib
    The price depends on the options chosen on the product page

    From $77.00

  • ASP 3026
    2005
    ASP 3026
    The price depends on the options chosen on the product page

    From $88.00

  • AZD3463
    2153
    AZD3463
    The price depends on the options chosen on the product page

    From $115.50

  • LDK 378
    2224
    LDK 378
    The price depends on the options chosen on the product page

    From $104.50

  • GSK 1838705A
    2267
    GSK 1838705A
    The price depends on the options chosen on the product page

    From $121.00

  • KRCA 0008
    2294
    KRCA 0008
    The price depends on the options chosen on the product page

    From $104.50

  • PF 06463922
    2600
    PF 06463922
    The price depends on the options chosen on the product page

    From $115.50

  • Brigatinib
    2978
    Brigatinib
    The price depends on the options chosen on the product page

    From $88.00

  • CEP-28122
    3931
    CEP-28122
    The price depends on the options chosen on the product page

    From Inquiry

  • XL-228
    3973
    XL-228
    The price depends on the options chosen on the product page

    From Inquiry

12 Items

More About Kinases (Tyrosine Specific Protein)

A small individual group of tyrosine kinase inhibitors is specifically targeting oncogenic fusion proteins. The expression of these proteins is caused by a reciprocal translocation between chromosomes, 9 and 22 in case of the BCR-ABL fusion protein. About 95% of the patients suffering from chronic myelogenous leukaemia show expression of this particular protein, yet it is also found in two other acute forms of leukaemia[1],[2]. Our product line includes both the very first drug registered on the market inhibiting this specific tyrosine kinase (Axon 1394: STI 571 or Imatinib (Novartis)), as well as well-known follow-up inhibitors, being more potent and/or more active against the emerging Gleevec/Glivec resistant BCR-ABL clones that originate from point mutations inside the kinase domain of the Bcr-Abl protein and disrupt the binding site of Imatinib on the tyrosine kinase (e.g. Axon 1392 and Axon 1396 (Dasatinib and Nilotinib resp.)[3]

[1] The molecular genetics ofPhiladelphia chromosome-positive leukemias. Kurzrock, R., Gutterman, J. Talpaz, M. N. Engl. J. Med. 1988, 319, 990-998.
[2] Dasatinib in imatinib-resistantPhiladelphia chromosome-positive leukemias. Talpaz M, Shah NP, Kantarjian H, et al. N. Engl. J. Med. 2006, 354 2531–2541.
[3] BCR-ABL tyrosine kinase inhibitors in the treatment ofPhiladelphia chromosome positive chronic myeloid leukemia: a review. An, X.; Tiwari, A.; Sun, Y.; Ding, P.; Ashby Jr, C.; Chen, Z. Leukemia research 2010, 34, 1255–1268.

 

Loading...